Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method.
Capillary isoelectric focusing (CIEF) with whole column imaging detection (WCID) was used to investigate drug-protein interactions. This study was designed to examine the interaction between the platinum-based anticancer drug, oxaliplatin, with human serum albumin (HSA) in aqueous solution at physiological pH with drug concentrations of 10 to 100 microM and a constant concentration of HSA (5.0 x 10(-5)M). The reaction mixtures were incubated for 0, 0.5, 1, 12, 24, 48 and 72 h at 37 degrees C in a water bath. The CIEF results indicate that with increasing the drug concentration, the complex formation of protein adducts increased compared to low-drug concentrations and major structural changes were observed as the incubation time progressed. The altered CIEF profile demonstrated the possible conformation change due to the binding of the drug. Results also showed a significant protein's pI shift for higher HSA-oxaliplatin incubation ratios. Furthermore, spectroscopic evidence shows that oxaliplatin caused the fluorescence quenching of HSA by formation of HSA-oxaliplatin complex. Using the Stern-Volmer equation, the quenching constants were calculated in the linear range. The quenching rate constants K(q) at three different temperatures indicating the presence of static quenching mechanism in the interactions of oxaliplatin with HSA. This paper describes the validity of the CIEF-WCID technique for the study of protein-drug interactions and provides useful information and insight into the interaction of anticancer drugs with HSA.
Lemma
Tibebe
T
Department of Chemistry, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada.
Pawliszyn
Janusz
J
D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism; D019075:Electrophoresis, Capillary / Q000379:methods; D006801:Humans; D007525:Isoelectric Focusing / Q000379:methods; D009944:Organoplatinum Compounds / Q000737:chemistry / Q000378:metabolism*; D000077150:Oxaliplatin; D012709:Serum Albumin / Q000378:metabolism*; D013050:Spectrometry, Fluorescence / Q000379:methods*; D013696:Temperature
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D012709:Serum Albumin; D000077150:Oxaliplatin